Pfizer Inc. (PFE)

36.23
0.46 1.30
NYSE : Health Technology
Prev Close 36.69
Open 36.38
Day Low/High 36.23 / 36.59
52 Wk Low/High 33.97 / 46.47
Volume 16.41M
Avg Volume 25.32M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 201.94B
EPS 1.90
P/E Ratio 16.44
Div & Yield 1.44 (3.90%)
Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets were higher Tuesday after starting Tuesday's session off in the green.

New Records as Dow and Other Indexes Post Gains on Tentative Mexico Trade Deal

New Records as Dow and Other Indexes Post Gains on Tentative Mexico Trade Deal

The S&P 500 and Nasdaq set record highs as stocks rose Monday after the U.S. and Mexico reached a tentative trade agreement.

Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented As Late-Breaking Data At The ESC Congress 2018

Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented As Late-Breaking Data At The ESC Congress 2018

Pfizer Inc. (NYSE:PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed tafamidis significantly reduced the hierarchical combination of both all-cause mortality and frequency of...

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 8/24/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 8/24/18)

Jim Cramer explains the art and science of technical analysis. Plus, he has next week's game plan.

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Pfizer Reached Our Price Target, So We Could Pause Here Before Heading Higher

Pfizer Reached Our Price Target, So We Could Pause Here Before Heading Higher

Traders should raise sell stops to just above $40 from below $35.50

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Why Pay a Premium for Estee Lauder?

Why Pay a Premium for Estee Lauder?

EL's stock is up despite a guidance cut.

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.

Investors May Have Omarosa to Thank for Pretty Good Week

Investors May Have Omarosa to Thank for Pretty Good Week

Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.

Walmart's Assault on Amazon Looks as if It's Starting to Pay Off in a Big Way

Walmart's Assault on Amazon Looks as if It's Starting to Pay Off in a Big Way

Retail earnings are in full swing with results from Walmart and J.C. Penney. All eyes still on the cannabis space. Big day for tool king Stanley Black & Decker.

Buy Stocks That Are Down, Not Up, Here

Buy Stocks That Are Down, Not Up, Here

Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Time to brace for a summer pullback?

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.

Pfizer Becomes #12 Most Shorted Dow Stock, Replacing Coca-Cola

Pfizer Becomes #12 Most Shorted Dow Stock, Replacing Coca-Cola

The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Healthcare Bulls Are Feeling Great After Earnings

Healthcare Bulls Are Feeling Great After Earnings

Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorization In The European Union For Moderately To Severely Active Ulcerative Colitis

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorization In The European Union For Moderately To Severely Active Ulcerative Colitis

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with...

Dow, Nasdaq and S&P 500 End Higher on Tech Rebound

Dow, Nasdaq and S&P 500 End Higher on Tech Rebound

Major indexes gave ground in the final minutes of trade, but managed to stay in positive territory at the close.

Best Tech Stocks to Buy -- No Matter What Apple Reports

Best Tech Stocks to Buy -- No Matter What Apple Reports

Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.

Global Stocks Mixed Amid Extended Tech Woes; BoJ Moves Boost Bond Markets

Global Stocks Mixed Amid Extended Tech Woes; BoJ Moves Boost Bond Markets

Global stocks continued to edge lower Tuesday, as tech sector weakness bled into markets in Asia following last night's sell off on Wall Street, putting even more pressure on today's third quarter earnings report from Apple at the close of trading today.

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS (2).

Apple, Federal Reserve, Pfizer, General Electric, CBS - 5 Things You Must Know

Apple, Federal Reserve, Pfizer, General Electric, CBS - 5 Things You Must Know

U.S. stock futures are rising slightly on Tuesday ahead of earnings from Apple and as a two-day meeting of the Federal Reserve gets set to begin.

Pfizer Receives European Approval For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Receives European Approval For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™, 1 a biosimilar to Herceptin ®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing...

Dow Ends Near Day's Lows as Tech Slump Hits Shares

Dow Ends Near Day's Lows as Tech Slump Hits Shares

Stocks ended lower on weakness in tech shares and after a strong report from Caterpillar proved insufficient to prop up the Dow.

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.

Earnings On Pace For Most 'Beats' in a Decade as Tariffs Pose Few Concerns

Earnings On Pace For Most 'Beats' in a Decade as Tariffs Pose Few Concerns

U.S. companies are on pace for one of the best earnings seasons in a decade, according to mid-term data from FactSet, with most firms appearing to have little or no concern for the impact of trade and tariffs on their bottoms lines over the coming months.

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Shares fell on Friday morning despite positive results for the second quarter.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

TheStreet Quant Rating: B (Buy)